Citicoline
- Generic Name
- Citicoline
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H26N4O11P2
- CAS Number
- 987-78-0
- Unique Ingredient Identifier
- 536BQ2JVC7
- Background
Citicoline is a donor of choline in biosynthesis of choline-containing phosphoglycerides. It has been investigated for the treatment, supportive care, and diagnosis of Mania, Stroke, Hypomania, Cocaine Abuse, and Bipolar Disorder, among others.
- Indication
主要用于急性颅脑外伤和脑手术后的意识障碍，以及脑卒中而致偏瘫的患者；也用于耳鸣及神经性耳聋、急性中毒、感染、大面积脑梗死所致的昏迷和意识障碍、帕金森病、急性胰腺炎；对缺血性脑血管病和血管性痴呆也有一定疗效,但对颅内出血引起的意识障碍效果较差。
- Associated Conditions
- Degenerative Brain Disorder, Parkinsonian Syndromes
- Associated Therapies
- -
ICTUS Study: International Citicoline Trial on Acute Stroke
- Conditions
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2012-06-20
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 2298
- Registration Number
- NCT00331890
- Locations
- 🇩🇪
Klinikum AltenburgerLand GmbH, Altenburg, Germany
🇩🇪Universitätsklinikum Erlangen, Erlangen, Germany
🇩🇪Johannes Wesling Klinikum Minden, Minden, Germany
Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 44
- Registration Number
- NCT00223236
- Locations
- 🇺🇸
The UT Southwestern Medical Center of Dallas, Dallas, Texas, United States
Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-10-22
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT00158249
- Locations
- 🇺🇸
McLean Hospital, Department of Psychiatry, Belmont, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.